Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
July 25, 2019 08:00 ET | Adaptimmune Therapeutics plc
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019...
Adaptimmune logo Colour_white background_no strap.jpg
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
August 15, 2018 07:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a favorable review...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
June 04, 2018 07:30 ET | Adaptimmune Therapeutics plc
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -              - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study...